CD274 and glioblastoma: Although anti-PD-1 monotherapy has failed to show efficacy in randomized phase III clinical trials for either recurrent or newly diagnosed GBM, combined treatments along with targeting of the PD-1/PD-L1 axis are currently under investigation [125].